{"id":90,"date":"2026-11-04T18:42:02","date_gmt":"2026-11-04T07:42:02","guid":{"rendered":"https:\/\/pressuraneuro.com\/newsite\/?page_id=90"},"modified":"2026-11-20T11:38:51","modified_gmt":"2026-11-20T00:38:51","slug":"home","status":"publish","type":"page","link":"https:\/\/pressuraneuro.com\/newsite\/","title":{"rendered":"Home"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;30px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;90%&#8221; max_width=&#8221;1280px&#8221; custom_padding=&#8221;10px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_font=&#8221;Instrument Sans|500|||||||&#8221; header_text_color=&#8221;#071240&#8243; text_orientation=&#8221;center&#8221; custom_margin=&#8221;0px||20px||false|false&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h1>PresSura <span style=\"color:#2563EB\">Neuro<\/span><\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; disabled_on=&#8221;on|off|off&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;90%&#8221; max_width=&#8221;1600px&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/banner-images-image-1.png&#8221; alt=&#8221;Hero image 1 \u2014 glowing neural network&#8221; title_text=&#8221;banner-images-image-1&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/banner-images-image-2.png&#8221; alt=&#8221;Hero image 2 \u2014 female medical researcher&#8221; title_text=&#8221;banner-images-image-2&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/banner-images-image-3.png&#8221; alt=&#8221;Hero image 3 \u2014 blue brain imaging&#8221; title_text=&#8221;banner-images-image-3&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_class=&#8221;pn-about-section&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row disabled_on=&#8221;off|on|on&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/banner.png&#8221; title_text=&#8221;banner&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_2,1_2&#8243; custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;90%&#8221; max_width=&#8221;1280px&#8221; custom_padding=&#8221;55px||20px||false|false&#8221; custom_padding_tablet=&#8221;55px||20px||false|false&#8221; custom_padding_phone=&#8221;30px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;LEAD PROGRAMME&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;|600|||||||&#8221; text_text_color=&#8221;#071240&#8243; header_2_font=&#8221;|500|||||||&#8221; header_2_font_size=&#8221;42px&#8221; header_2_line_height=&#8221;1.15em&#8221; header_2_text_align_tablet=&#8221;&#8221; header_2_text_align_phone=&#8221;center&#8221; header_2_text_align_last_edited=&#8221;on|phone&#8221; header_2_font_size_tablet=&#8221;42px&#8221; header_2_font_size_phone=&#8221;30px&#8221; header_2_font_size_last_edited=&#8221;on|phone&#8221; text_orientation_tablet=&#8221;&#8221; text_orientation_phone=&#8221;center&#8221; text_orientation_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>LEAD PROGRAMME<\/p>\n<h2>Moderate to Severe<br \/>Traumatic Brain Injury.<\/h2>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#071240&#8243; text_font_size=&#8221;16px&#8221; text_orientation_tablet=&#8221;&#8221; text_orientation_phone=&#8221;center&#8221; text_orientation_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>EU-C-001 is a compound targeting the control of elevated intracranial pressure following traumatic brain injury. It is in a Phase 2A double-blind trial across multiple countries, and enrolment is complete. The trial follows a Phase 1 programme and an open-label phase.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;\/newsite\/science\/&#8221; button_text=&#8221;EXPLORE SCIENCE&#8221; button_alignment=&#8221;left&#8221; button_alignment_tablet=&#8221;left&#8221; button_alignment_phone=&#8221;center&#8221; button_alignment_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;12px&#8221; button_text_color=&#8221;#FFFFFF&#8221; button_bg_color=&#8221;#2563EB&#8221; button_border_width=&#8221;0px&#8221; button_border_radius=&#8221;0px&#8221; button_letter_spacing=&#8221;0px&#8221; button_font=&#8221;Instrument Sans|600|||||||&#8221; custom_padding=&#8221;12px|20px|12px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row custom_padding_last_edited=&#8221;on|phone&#8221; disabled_on=&#8221;on|on|off&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; max_width=&#8221;1320px&#8221; custom_padding=&#8221;||80px||false|false&#8221; custom_padding_tablet=&#8221;||80px||false|false&#8221; custom_padding_phone=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/moderate-to-severe-traumatic-brain-injury.png&#8221; alt=&#8221;Traumatic brain injury emergency treatment image&#8221; title_text=&#8221;moderate-to-severe-traumatic-brain-injury&#8221; align=&#8221;center&#8221; force_fullwidth=&#8221;on&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; module_class=&#8221;pn-about-section pn-about-details&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#ffffff&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;||-50px||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding=&#8221;||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; custom_padding_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width=&#8221;90%&#8221; width_tablet=&#8221;90%&#8221; width_phone=&#8221;95%&#8221; width_last_edited=&#8221;on|desktop&#8221; max_width=&#8221;1320px&#8221; custom_padding=&#8221;||90px||false|false&#8221; custom_padding_tablet=&#8221;||90px||false|false&#8221; custom_padding_phone=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;About PresSura Neuro.&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_2_font=&#8221;Instrument Sans|500|||||||&#8221; header_2_text_color=&#8221;#071240&#8243; header_2_font_size=&#8221;44px&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<h2>About PresSura Neuro.<\/h2>\n<p>[\/et_pb_text][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/about-pres-sura-neuro-image.png&#8221; alt=&#8221;Doctor reviewing neurological scans on tablet&#8221; title_text=&#8221;about-pres-sura-neuro-image&#8221; admin_label=&#8221;Image&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;Instrument Sans|400|||||||&#8221; text_text_color=&#8221;#071240&#8243; text_font_size=&#8221;16px&#8221; text_line_height=&#8221;1.8em&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>PresSura Neuro is a biopharmaceutical company, developing EU-C-001 for the treatment of:<\/p>\n<div class=\"pn-condition-list\">\n<div class=\"pn-condition-item\"><img decoding=\"async\" src=\"https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/list-item-icon-1.png\" alt=\"\" aria-hidden=\"true\" \/>Elevated intracranial pressure (ICP) following moderate to severe traumatic brain injury (TBI)<\/div>\n<div class=\"pn-condition-item\"><img decoding=\"async\" src=\"https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/stroke-other-neurological-conditions-icon-1.png\" alt=\"\" aria-hidden=\"true\" \/>Stroke<\/div>\n<div class=\"pn-condition-item\"><img decoding=\"async\" src=\"https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/list-item-icon-8.png\" alt=\"\" aria-hidden=\"true\" \/>The effects from concussions including CTE, TES and PCS<\/div>\n<\/div>\n<p>PresSura Neuro is targeting conditions that currently have no regulatory approved medications.<\/p>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;\/newsite\/development-programme\/&#8221; button_text=&#8221;DEVELOPMENT PROGRAMME&#8221; button_alignment=&#8221;left&#8221; button_alignment_tablet=&#8221;left&#8221; button_alignment_phone=&#8221;center&#8221; button_alignment_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;12px&#8221; button_text_color=&#8221;#FFFFFF&#8221; button_bg_color=&#8221;#2563EB&#8221; button_border_width=&#8221;0px&#8221; button_border_radius=&#8221;0px&#8221; button_letter_spacing=&#8221;0px&#8221; button_font=&#8221;Instrument Sans|600|||||||&#8221; custom_padding=&#8221;12px|20px|12px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row disabled_on=&#8221;on|on|off&#8221; module_class=&#8221;pn-about-decoration&#8221; _builder_version=&#8221;4.27.9&#8243; positioning=&#8221;absolute&#8221; position_origin_a=&#8221;bottom_right&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/pres-sura-image.png&#8221; align=&#8221;right&#8221; module_class=&#8221;pn-corner-graphic pn-corner-right&#8221; _builder_version=&#8221;4.27.9&#8243; width=&#8221;480px&#8221; max_width=&#8221;480px&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; custom_padding_last_edited=&#8221;on|phone&#8221; module_class=&#8221;pn-team-section pn-team-gradient&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#ffffff&#8221; custom_padding=&#8221;60px||30px||false|false&#8221; custom_padding_tablet=&#8221;60px||30px||false|false&#8221; custom_padding_phone=&#8221;0px||||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row column_structure=&#8221;2_5,3_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; width_tablet=&#8221;&#8221; width_phone=&#8221;95%&#8221; width_last_edited=&#8221;on|phone&#8221; max_width=&#8221;1320px&#8221; custom_margin_tablet=&#8221;&#8221; custom_margin_phone=&#8221;-150px||||false|false&#8221; custom_margin_last_edited=&#8221;on|phone&#8221; custom_padding=&#8221;0px||70px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;2_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/our-team-image-1.png&#8221; alt=&#8221;Scientist working at a laboratory microscope&#8221; title_text=&#8221;our-team-image-1&#8243; align=&#8221;center&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][et_pb_column type=&#8221;3_5&#8243; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_text admin_label=&#8221;PresSura Neuro is the trading name for Eustralis Pharmaceuticals Ltd, based in Melbourne, Australia. Formed in 2005; has licensed compounds from Hoffmann\u2013La Roche (Switzerland) to develop solutions for neurological indications for which there are currently no treatments.&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; header_3_font=&#8221;|300|||||||&#8221; header_3_text_color=&#8221;#071240&#8243; header_3_font_size=&#8221;29px&#8221; header_3_line_height=&#8221;1.3em&#8221; hover_enabled=&#8221;0&#8243; header_3_text_align_tablet=&#8221;&#8221; header_3_text_align_phone=&#8221;center&#8221; header_3_text_align_last_edited=&#8221;on|phone&#8221; header_3_font_size_tablet=&#8221;29px&#8221; header_3_font_size_phone=&#8221;24px&#8221; header_3_font_size_last_edited=&#8221;on|phone&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]<\/p>\n<h3>PresSura Neuro is the trading name for Eustralis Pharmaceuticals Ltd, based in Melbourne, Australia. Formed in 2005, PresSura Neuro licensed compounds from Hoffmann-La Roche (Switzerland) to develop solutions for a range of neurological conditions for which there are currently no treatments including TBI, stroke and concussion\/PCS.<\/h3>\n<p>[\/et_pb_text][et_pb_button button_url=&#8221;\/newsite\/team\/&#8221; button_text=&#8221;OUR TEAM&#8221; button_alignment=&#8221;left&#8221; button_alignment_tablet=&#8221;left&#8221; button_alignment_phone=&#8221;center&#8221; button_alignment_last_edited=&#8221;on|phone&#8221; _builder_version=&#8221;4.27.9&#8243; _module_preset=&#8221;default&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;12px&#8221; button_text_color=&#8221;#FFFFFF&#8221; button_bg_color=&#8221;#2563EB&#8221; button_border_width=&#8221;0px&#8221; button_border_radius=&#8221;0px&#8221; button_letter_spacing=&#8221;0px&#8221; button_font=&#8221;Instrument Sans|600|||||||&#8221; custom_padding=&#8221;12px|20px|12px|20px|true|true&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_button][\/et_pb_column][\/et_pb_row][et_pb_row module_class=&#8221;pn-team-decoration&#8221; _builder_version=&#8221;4.27.9&#8243; positioning=&#8221;absolute&#8221; position_origin_a=&#8221;bottom_left&#8221; width=&#8221;100%&#8221; max_width=&#8221;100%&#8221; custom_padding=&#8221;0px||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.27.9&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_image src=&#8221;https:\/\/pressuraneuro.com\/newsite\/wp-content\/uploads\/2026\/11\/our-team-image-2.png&#8221; module_class=&#8221;pn-corner-graphic pn-corner-left&#8221; _builder_version=&#8221;4.27.9&#8243; width=&#8221;300px&#8221; max_width=&#8221;300px&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PresSura NeuroLEAD PROGRAMME Moderate to SevereTraumatic Brain Injury.EU-C-001 is a compound targeting the control of elevated intracranial pressure following traumatic brain injury. It is in a Phase 2A double-blind trial across multiple countries, and enrolment is complete. The trial follows a Phase 1 programme and an open-label phase.About PresSura Neuro.PresSura Neuro is a biopharmaceutical company, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-90","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/pages\/90","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/comments?post=90"}],"version-history":[{"count":62,"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/pages\/90\/revisions"}],"predecessor-version":[{"id":502,"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/pages\/90\/revisions\/502"}],"wp:attachment":[{"href":"https:\/\/pressuraneuro.com\/newsite\/wp-json\/wp\/v2\/media?parent=90"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}